A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B

NCT02598063 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: Adefovir dipivoxil
DRUG: Lamivudine
DRUG: Peginterferon alfa-2a

Sponsor

Hoffmann-La Roche